Method of Treating Hepatitis C Virus Infection With a Small Molecule CHK2 Inhibitor
Posted Mar 22 2012 8:00pm
Description of Invention: DNA damage sensors such as Checkpoint Kinase 2 (Chk2) are key regulators of the cellular DNA damage response that limits cell-cycle progression in response to DNA damage. It has been reported that these DNA damage sensors also play a key role in Hepatitis C virus (HCV) replication. The subject technology are small molecule CHK2 kinase inhibitors that have been shown to have promising activity against HCV replication. The compounds were discovered by high throughput screening of chemical libraries with more than 150,000 compounds. These novel compounds can potentially be used in combination with other anti-HCV drugs or interferon and represent a novel target for treating HCV. In vitro antiviral assay data, as well as preliminary in vitro and in vivo pharmokinetic data are available upon request.
Applications: The subject technology can potentially be developed into anti-HCV therapeutics, particularly in combination with other anti-HCV therapeutics.
Advantages: The subject technology represents a novel and promising target for treating HCV infection and thus, has the potential to increase the efficacy of other HCV antivirals that directly target HCV in a multi-drug formulation. Furthermore, since the subject technology targets a cellular protein necessary for HCV replication and not the virus itself, the emergence of viral resistance against the subject technology could be low or more delayed.
In vitro data available
In vivo data available (animal)
Inventors: Yves G Pommier (NCI) Robert H Shoemaker (NCI) Dominic A Scudiero (NCI) Andrew G Jobson (NCI) David S Waugh (NCI) George T Lountos (NCI)
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5018 Fax: 301-402-0220